Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States

被引：1
|
作者：
Vachhani, Pankit [1 ]
Abbas, Jonathan A. [2 ]
Flahavan, Evelyn M. [3 ]
Ma, Esprit [4 ]
Xu, Tao [5 ]
Jin, Huan [4 ]
Montez, Melissa [4 ]
Huang, Weize [4 ]
Gershon, Anda [4 ]
Ku, Grace [4 ]
Flores, Brannon [4 ]
Onishi, Maika [4 ]
Bui, Cat N. [6 ]
Donnellan, William [2 ]
机构：
[1] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[2] Tennessee Oncol, Nashville, TN USA
[3] Roche Prod Ltd, Welwyn Garden City, Herts, England
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] AbbVie Inc, N Chicago, IL USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147851
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Treatment Patterns and Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMA) in the United States (US)
    Pardee, Timothy S.
    Oschwald, Jessica
    Ma, Esprit
    Xu, Tao
    Montez, Melissa
    Ramsingh, Giridharan
    Hong, Wan-Jen
    Choi, Michelle
    Flahavan, Evelyn M.
    [J]. BLOOD, 2020, 136
  • [2] Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications
    Donnellan, William
    Xu, Tao
    Ma, Esprit
    Jin, Huan
    Montez, Melissa
    Choi, Michelle
    Ku, Grace
    Rajeswaran, Raj Anand
    Ramsingh, Giridharan
    Flahavan, Evelyn M.
    [J]. BLOOD, 2020, 136
  • [3] Real World Data on Clinical Outcomes of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated With Hypomethylating Agents (HMA) Plus Shorter Duration of Venetoclax (VEN) at a General Hospital
    Khan, Hina
    Yohannan, Binoy
    Cervoni-Curet, Frances
    Rios, Adan
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S262 - S262
  • [4] Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes
    Ghorab, Ahmad
    Litzow, Mark
    Gangat, Naseema
    Al-Kali, Aref
    Shah, Mithun
    Murthy, Hemant
    Alkhateeb, Hasan
    Begna, Kebede
    Patnaik, Mrinal
    Foran, James
    Badar, Talha
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S306 - S306
  • [5] Correlative Biomarkers of Response to Venetoclax (VEN) in Combination with Chemotherapy or Hypomethylating Agents (Hma) in Elderly Untreated Patients with Acute Myeloid Leukemia (AML)
    Chyla, B.
    Popovic, R.
    Potluri, J.
    Hayslip, J.
    Huang, X.
    Mabry, M.
    Bhathena, A.
    [J]. ANNALS OF HEMATOLOGY, 2017, 96 : S84 - S85
  • [6] Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)
    Tan, Irena
    Schwede, Matthew
    Phan, Paul
    Yin, Raymond
    Zhang, Tian Y.
    Mannis, Gabriel N.
    [J]. BLOOD, 2021, 138
  • [7] Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)
    Bell, Jill A.
    Galaznik, Aaron
    Farrelly, Eileen
    Murty, Sharanya
    Ogbonnaya, Augustina
    Eaddy, Michael T.
    Fram, Robert J.
    Faller, Douglas V.
    Kota, Vamsi
    [J]. BLOOD, 2017, 130
  • [8] Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)
    Ball, Brian J.
    Arslan, Shukaib
    Koller, Paul
    Ngo, Dat
    Afkhami, Michelle
    Salhotra, Amandeep
    Al-Malki, Monzr
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Otoukesh, Salman
    Amanam, Idoroenyi
    Pourhassan, Hoda
    Artz, Andrew
    Curtin, Peter
    Stein, Anthony
    Nakamura, Ryotaro
    Marcucci, Guido
    Smith, Eileen
    Pullarkat, Vinod
    Aldoss, Ibrahim
    [J]. LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3232 - 3236
  • [9] How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
    Brian A. Jonas
    Daniel A. Pollyea
    [J]. Leukemia, 2019, 33 : 2795 - 2804
  • [10] How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
    Jonas, Brian A.
    Pollyea, Daniel A.
    [J]. LEUKEMIA, 2019, 33 (12) : 2795 - 2804
12345